Annotation Detail
Information
- Associated Genes
- ROS1
- Associated Variants
- ROS1 CD74-ROS1 G2032R
- Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- Preclinical study analyzing the efficacy of dual ROS1/ALK and more specific ROS1 inhibitors on cell lines (Ba/F3) expressing CD74-ROS1 with and without the G2032R mutation. Selective ROS1 inhibitors retained activity against the G2032R mutation (cabozatinib, foretinib), whereas dual ALK/ROS inhibitors (crizotinib, brigatinib, ceritinib, AZD3463) or ALK-selective inhibitors (alectinib) were ineffective.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1249
- Gene URL
- https://civic.genome.wustl.edu/links/genes/4941
- Variant URL
- https://civic.genome.wustl.edu/links/variants/465
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Foretinib,Cabozantinib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26372962
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Cabozantinib | Sensitivity | true |
| Foretinib | Sensitivity | true |